MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

MaxCyte (Nasdaq: MXCT) granted inducement awards tied to the appointment of Parmeet Ahuja as Chief Financial Officer. The Compensation Committee approved stock options for 375,000 shares (10-year term, exercise price $0.676) and 187,500 RSUs.

Grant dates: stock options March 30, 2026; RSUs April 15, 2026. Options vest 25% after one year then monthly over 36 months; RSUs vest 25% after one year then in three equal annual installments, each subject to continued service. Disclosed under Nasdaq Listing Rule 5635(c)(4).

Positive

• New CFO hire with structured long-term equity incentive aligning interests
• Significant equity grants: 375,000 options and 187,500 RSUs
• Exercise price set at recent market close: $0.676

Negative

• Potential dilution from 562,500 share-equivalent inducement awards

Key Figures

Stock options granted: 375,000 shares RSU award: 187,500 shares Exercise price: $0.676 +5 more

8 metrics

Stock options granted 375,000 shares Inducement award under 2026 Inducement Plan

RSU award 187,500 shares Service-based RSU inducement grant

Exercise price $0.676 Closing price on March 30, 2026 for stock options

Option vesting period 4 years 25% after one year, remainder monthly over 36 months

RSU vesting period 4 years 25% after first anniversary, then three annual installments

Option term 10 years Maximum term of inducement stock options

Option grant date March 30, 2026 Grant date for stock option inducement award

RSU grant date April 15, 2026 Grant date for RSU inducement award

Market Reality Check

Price: $0.7025 Vol: Volume 883,932 is at 0.86...

normal vol

$0.7025 Last Close

Volume Volume 883,932 is at 0.86x the 20-day average of 1,032,248, suggesting typical activity pre-announcement. normal

Technical Shares at $0.6762 are trading below the $1.48 200-day moving average and near the 52-week low of $0.6434.

Peers on Argus

MXCT was down 1.08% while momentum data only flags peer LNSR moving up about 4.4...

1 Up

MXCT was down 1.08% while momentum data only flags peer LNSR moving up about 4.46%, indicating this equity-grant news appears company-specific rather than part of a broader sector move.

Historical Context

5 past events · Latest: Mar 24 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 24	Earnings results	Negative	-6.8%	Reported 2025 revenue decline and trimmed 2026 outlook versus prior year.
Mar 23	CFO appointment	Positive	-1.1%	Named new CFO with over 20 years of finance leadership experience.
Feb 24	Product launch	Positive	+5.0%	Launched ExPERT DTx, a 96-well high-throughput electroporation platform.
Feb 23	Earnings date set	Neutral	+5.0%	Announced timing and webcast details for Q4 and FY2025 results release.
Jan 12	Preliminary earnings	Negative	-4.9%	Released preliminary 2025 results highlighting a challenging year despite guidance in line.

Pattern Detected

Recent news often saw price declines on earnings-related updates, while product and scheduling news produced mixed to positive reactions, with one CFO announcement coinciding with a mild decline.

Recent Company History

Over the past six months, MXCT reported weaker 2025 results and trimmed 2026 guidance, with shares falling after both preliminary and final earnings updates. Product news such as the ExPERT DTx™ launch on Feb 24, 2026 coincided with a 5.01% gain, and an earnings-date announcement the prior day also matched that move. The recent CFO appointment on Mar 23, 2026 aligned with a modest 1.08% decline. Today’s inducement grants tie directly to that CFO transition narrative.

Market Pulse Summary

This announcement details standard inducement equity awards for the new CFO, including 375,000 stock...

Analysis

This announcement details standard inducement equity awards for the new CFO, including 375,000 stock options at an exercise price of $0.676 and 187,500 RSUs vesting over four years. It follows recent disclosures of revenue declines, a $44.6M 2025 net loss, and a Nasdaq bid-price deficiency notice. Investors may track how leadership changes, compensation structure, and upcoming execution on guidance interact with these earlier financial and listing risks.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock unit, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock unit financial

"a service-based restricted stock unit (“RSU”) award with respect to 187,500 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

exercise price financial

"The stock options have a ten-year term and an exercise price of $0.676"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 187,500 shares of MaxCyte’s common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of March 30, 2026 with respect to the stock option award and April 15, 2026 with respect to the RSU award, as an inducement material to Mr. Ahuja entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options are scheduled to vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to Mr. Ahuja’s continuous service with MaxCyte through the applicable vesting dates. The stock options have a ten-year term and an exercise price of $0.676, the closing price of MaxCyte’s common stock as reported by Nasdaq on March 30, 2026.

The RSUs are scheduled to vest over four years, with 25% vesting on the first anniversary of March 30, 2026 and the remainder vesting in three equal annual installments thereafter, subject to Mr. Ahuja’s continuous service with MaxCyte through the applicable vesting dates.

MaxCyte is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

MaxCyte Contacts:

Investor Relations

Gilmartin Group

David Deuchler, CFA

ir@maxcyte.com 

Media Contact

Oak Street Communications

Kristen White

+1 415-608-6060

kristen@oakstreetcommunications.com 

FAQ

What inducement awards did MaxCyte (MXCT) grant to its new CFO Parmeet Ahuja?

The company granted stock options for 375,000 shares and RSUs for 187,500 shares. According to the company, the options carry a ten-year term and the RSUs are service-based with multi-year vesting.

When do the MXCT stock options and RSUs granted to Parmeet Ahuja vest?

Options vest 25% after one year, then monthly over 36 months; RSUs vest 25% after one year, then in three equal annual installments. According to the company, vesting is subject to continuous service through each vesting date.

What exercise price was set for MaxCyte (MXCT) stock options granted on March 30, 2026?

The exercise price is $0.676, equal to the Nasdaq closing price on March 30, 2026. According to the company, this price applies to the 10-year option awards issued as an inducement.

Why did MaxCyte (MXCT) disclose these awards under Nasdaq Listing Rule 5635(c)(4)?

MaxCyte disclosed the grants because inducement equity awards issued in connection with a new executive’s hire require Nasdaq reporting. According to the company, the awards were material to Mr. Ahuja taking employment and follow Listing Rule 5635(c)(4).

How might MaxCyte's (MXCT) inducement awards to the CFO affect shareholders?

The awards represent potential dilution equal to 562,500 share equivalents if fully issued and exercised. According to the company, the grants are standard inducement compensation tied to multi-year vesting and continued service.